Beta Blockers for Atrial Fibrillation Rate Control

Introduction to Beta Blocker Therapy

The American College of Cardiology recommends beta blockers as first-line agents for rate control in atrial fibrillation, with metoprolol being the most commonly used agent for both acute and chronic management 1, 2

Metoprolol is the primary beta blocker for AFib rate control, with acute IV dosing of 2.5-5 mg IV bolus over 2 minutes, up to 3 doses, and chronic oral dosing of 25-200 mg twice daily (tartrate) or 50-400 mg once or twice daily (succinate/extended-release) 1, 2
Esmolol is preferred when rapid titration is needed in acute settings, with a loading dose of 500 mcg/kg IV over 1 minute and maintenance infusion of 50-300 mcg/kg/min IV 1, 3

For patients with normal left ventricular function (LVEF ≥40%), the American Heart Association recommends choosing either beta blockers or non-dihydropyridine calcium channel blockers as first-line therapy, with beta blockers achieving rate control targets in 70% of patients compared to 54% with calcium channel blockers 4, 5
For patients with heart failure or reduced LVEF (<40%), the American College of Cardiology recommends using beta blockers as first-line therapy with the smallest effective dose, avoiding non-dihydropyridine calcium channel blockers entirely 4, 3

The European Society of Cardiology recommends an initial target heart rate of <110 bpm at rest (lenient control) and an optimal target of 60-80 bpm at rest and 90-115 bpm during moderate exercise (strict control) for symptomatic patients 4
Lenient rate control (<110 bpm) may be reasonable in asymptomatic patients with preserved LV function, while strict rate control (resting heart rate <80 bpm) is reasonable for symptomatic management 2

The American College of Cardiology recommends adding digoxin to the initial beta blocker if monotherapy fails to achieve target heart rate, with the combination providing superior rate control at rest and during exercise compared to either agent alone 4, 3

Absolute contraindications to beta blockers include severe bradycardia or second/third-degree AV block without pacemaker, decompensated heart failure, active asthma or severe bronchospasm, and Wolff-Parkinson-White syndrome with AFib 4, 3
Relative contraindications include hypotension, first-degree AV block, and renal impairment requiring dose adjustment of atenolol 4

The American Heart Association recommends digoxin as second-line therapy due to its ineffectiveness during exercise and delayed onset of action, with appropriate uses including physically inactive elderly patients, add-on therapy, and patients with heart failure as adjunctive therapy 5, 4

The European Society of Cardiology advises against relying on resting heart rate alone, using calcium channel blockers in heart failure with reduced ejection fraction, using beta blockers in Wolff-Parkinson-White syndrome, using digoxin as monotherapy in active patients, and forgetting to adjust atenolol dosing in renal impairment 1, 2, 3, 4, 5, 6

The American College of Cardiology notes that beta blockers do not reduce all-cause mortality in AFib patients with heart failure, but are still recommended based on symptomatic improvement, lack of harm, and good tolerability, with a hazard ratio of 0.97 (95% CI 0.83-1.14) 4